US Patent 7361752 RNAi modulation of MLL-AF4 and uses thereof

Patent 7361752 was granted and assigned to Alnylam Pharmaceuticals on April, 2008 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Alnylam Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

7361752

Date of Patent

April 22, 2008

Patent Application Number

11303367

Date Filed

December 14, 2005

Patent Primary Examiner

‌

Brian Whiteman

Patent abstract

The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7361752 RNAi modulation of MLL-AF4 and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API